12885_2017_3100_MOESM2_ESM.docx (79.77 kB)
Additional file 2: Table S2. of The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation
journal contribution
posted on 2017-03-01, 05:00 authored by D. Lundon, A. Boland, M. Prencipe, G. Hurley, A O’Neill, E. Kay, S. Aherne, P. Doolan, S. Madden, M. Clynes, C. Morrissey, J. Fitzpatrick, R. WatsonGenes predicted to by dysregulated in the studied PC3 model of Docetaxel Resistance. AG = aged matched control, D8 = docetaxel resistant subline, D12 = docetaxel resistant subline. FC = fold change. (DOCX 79 kb)
Funding
Science Foundation Ireland, Molecular Therapeutics for Cancer in Ireland
History
Usage metrics
Categories
- Biochemistry
- Space Science
- Cell Biology
- Genetics
- Molecular Biology
- Pharmacology
- Chemical Sciences not elsewhere classified
- Ecology
- Biological Sciences not elsewhere classified
- Mathematical Sciences not elsewhere classified
- Developmental Biology
- Cancer
- Hematology
- Infectious Diseases
- Plant Biology
- Virology
- Computational Biology
Keywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC